Oct 05, 2015
Pharmaceutical Executive
A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall. William Looney reports.
Oct 06, 2015
No-one can say England's Accelerated Access Review, which aims to “ensure that the UK is the fastest place in the world for the design, development and widespread adoption of medical innovations" isn't aiming high, writes Leela Barham.
Oct 05, 2015
As pharma continues to move towards "beyond the pill" strategies, better understanding of patients' sometimes paradoxical view of disease can help lead to strategies for helping them live more productive lives, writes Nick Hicks.
Sep 28, 2015
Casey McDonald previews pharma’s Oscars, the Prix Galien USA Awards, which this fall will bring some red carpet glamor and, hopefully, cheer to the industry.
Sep 17, 2015
Pharmaceutical Executive
Last week, the White House nominated Robert Califf to head FDA, long after he came to the agency in January 2015 as deputy commissioner for medical products and tobacco. But will he be confirmed, asks Jill Wechsler.
Sep 16, 2015
UNITE HERE, a labor union representing 270,000 workers people across Canada and the US, has questioned pharma’s connections to the influential and highly visible American Heart Association (AHA). Casey McDonald reports.
Sep 15, 2015
Leela Barham looks at the implications of another round of cuts due to England’s Cancer Drugs Fund in November.
Sep 14, 2015
Biopharma investment pundits have been having a field day, all but certain that Gilead will make a big (possibly transformative) move soon. Casey McDonald looks at reactions in the Twittersphere.
Sep 10, 2015
The issue of drug price controls in public prescription programs has long been a point of contention. But today, writes Tom Norton, as several historical and contemporary factors continue to line up, we may be on a pathway to changing that.
Sep 09, 2015
Pharmaceutical Executive
Amarin ruling puts pressure on FDA to reassess marketing rules, writes Jill Wechsler.